• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Translational evidence for RRM2 as a prognostic biomarker and therapeutic target in Ewing sarcoma.

作者信息

Ohmura Shunya, Marchetto Aruna, Orth Martin F, Li Jing, Jabar Susanne, Ranft Andreas, Vinca Endrit, Ceranski Katharina, Carreño-Gonzalez Martha J, Romero-Pérez Laura, Wehweck Fabienne S, Musa Julian, Bestvater Felix, Knott Maximilian M L, Hölting Tilman L B, Hartmann Wolfgang, Dirksen Uta, Kirchner Thomas, Cidre-Aranaz Florencia, Grünewald Thomas G P

机构信息

Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.

Division of Translational Pediatric Sarcoma Research (B410), German Cancer Research Center (DKFZ) & Hopp-Children's Cancer Center (KiTZ), Im Neuenheimer Feld 280, 69210, Heidelberg, Germany.

出版信息

Mol Cancer. 2021 Jul 27;20(1):97. doi: 10.1186/s12943-021-01393-9.

DOI:10.1186/s12943-021-01393-9
PMID:34315482
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8314608/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc56/8314608/ab80d4996576/12943_2021_1393_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc56/8314608/1fd018a512f4/12943_2021_1393_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc56/8314608/ab80d4996576/12943_2021_1393_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc56/8314608/1fd018a512f4/12943_2021_1393_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc56/8314608/ab80d4996576/12943_2021_1393_Fig2_HTML.jpg

相似文献

1
Translational evidence for RRM2 as a prognostic biomarker and therapeutic target in Ewing sarcoma.RRM2作为尤因肉瘤预后生物标志物和治疗靶点的转化证据。
Mol Cancer. 2021 Jul 27;20(1):97. doi: 10.1186/s12943-021-01393-9.
2
The translational repressor 4E-BP1 regulates RRM2 levels and functions as a tumor suppressor in Ewing sarcoma tumors.翻译后文本：翻译抑制因子 4E-BP1 调节 RRM2 水平，并作为尤文肉瘤肿瘤中的肿瘤抑制因子发挥作用。
Oncogene. 2021 Jan;40(3):564-577. doi: 10.1038/s41388-020-01552-0. Epub 2020 Nov 15.
3
Ewing sarcoma: current concepts in diagnosis and treatment.尤因肉瘤：诊断与治疗的当前概念
Curr Opin Pediatr. 2003 Feb;15(1):53-7. doi: 10.1097/00008480-200302000-00009.
4
Advances in the treatment of tumors arising in bone.骨肿瘤治疗的进展
Semin Oncol. 1974 Mar;1(1):47-55.
5
Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors.通过定量逆转录聚合酶链反应（Q-RTPCR）评估人类肿瘤中核糖核苷酸还原酶（RRM2）M2亚基的信使核糖核酸（mRNA），并通过绝对定量免疫荧光法（AQUA）评估其蛋白质表达。
Cancer Chemother Pharmacol. 2009 Jun;64(1):79-86. doi: 10.1007/s00280-008-0845-0. Epub 2008 Oct 22.
6
A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2).一种导致预后不良前列腺癌的新机制：DNA 修复基因核苷酸还原酶小亚基 M2（RRM2）的过表达。
Clin Cancer Res. 2019 Jul 15;25(14):4480-4492. doi: 10.1158/1078-0432.CCR-18-4046. Epub 2019 Apr 17.
7
Ribonucleotide reductase subunit M2 is a potential prognostic marker and therapeutic target for soft tissue sarcoma.核糖核苷酸还原酶亚基M2是软组织肉瘤的潜在预后标志物和治疗靶点。
Gene. 2022 Jan 15;808:145988. doi: 10.1016/j.gene.2021.145988. Epub 2021 Oct 5.
8
Update in treatment and targets in Ewing sarcoma.尤因肉瘤治疗方法的更新和靶点。
Hematol Oncol Clin North Am. 2013 Oct;27(5):1007-19. doi: 10.1016/j.hoc.2013.07.001. Epub 2013 Aug 3.
9
DSCAM-AS1 promotes tumor growth of breast cancer by reducing miR-204-5p and up-regulating RRM2.DSCAM-AS1 通过降低 miR-204-5p 并上调 RRM2 促进乳腺癌的肿瘤生长。
Mol Carcinog. 2019 Apr;58(4):461-473. doi: 10.1002/mc.22941. Epub 2018 Dec 21.
10
Highly personalized detection of minimal Ewing sarcoma disease burden from plasma tumor DNA.从血浆肿瘤DNA中高度个性化检测微小尤因肉瘤疾病负担。
Cancer. 2016 Oct;122(19):3015-23. doi: 10.1002/cncr.30144. Epub 2016 Jun 28.

引用本文的文献

1
Integration of scRNA-seq and ST-seq identifies hyperproliferative RRM2+ cells features and therapeutic targets in gastric cancer.单细胞RNA测序（scRNA-seq）与空间转录组测序（ST-seq）相结合，确定了胃癌中增殖性RRM2+细胞的特征和治疗靶点。
J Transl Med. 2025 Jul 15;23(1):795. doi: 10.1186/s12967-025-06847-y.
2
promotes the proliferation, migration, and invasion of osteosarcoma cells by increasing the intracellular iron content and expression.通过增加细胞内铁含量和表达来促进骨肉瘤细胞的增殖、迁移和侵袭。
Front Oncol. 2025 May 29;15:1567216. doi: 10.3389/fonc.2025.1567216. eCollection 2025.
3
Histone Deacetylase Inhibitors Target DNA Replication Regulators and Replication Stress in Ewing Sarcoma Cells.

本文引用的文献

1
Phase II trial of gemcitabine and nab-paclitaxel in patients with recurrent Ewing sarcoma: A report from the National Pediatric Cancer Foundation.吉西他滨联合 nab-紫杉醇治疗复发性尤文肉瘤的 II 期临床试验：来自国家儿科癌症基金会的报告。
Pediatr Blood Cancer. 2020 Jul;67(7):e28370. doi: 10.1002/pbc.28370. Epub 2020 May 9.
2
Cooperation of cancer drivers with regulatory germline variants shapes clinical outcomes.癌症驱动因素与调控性种系变异的合作塑造了临床结果。
Nat Commun. 2019 Sep 11;10(1):4128. doi: 10.1038/s41467-019-12071-2.
3
Combined use of subclinical hydroxyurea and CHK1 inhibitor effectively controls melanoma and lung cancer progression, with reduced normal tissue toxicity compared to gemcitabine.
组蛋白去乙酰化酶抑制剂靶向尤因肉瘤细胞中的DNA复制调节因子和复制应激。
Cancer Res Commun. 2025 Jun 1;5(6):1034-1048. doi: 10.1158/2767-9764.CRC-25-0058.
4
Ribonucleotide-diphosphate reductase subunit M2 (RRM2) expression and colorectal cancer invasiveness: a potential prognostic biomarker.核糖核苷酸二磷酸还原酶亚基M2（RRM2）表达与结直肠癌侵袭性：一种潜在的预后生物标志物。
Mol Biol Rep. 2025 May 7;52(1):447. doi: 10.1007/s11033-025-10510-6.
5
Combined inhibition of ribonucleotide reductase and WEE1 induces synergistic anticancer activity in Ewing's sarcoma cells.联合抑制核糖核苷酸还原酶和WEE1在尤因肉瘤细胞中诱导协同抗癌活性。
BMC Cancer. 2025 Feb 17;25(1):277. doi: 10.1186/s12885-025-13691-2.
6
Osalmid sensitizes clear cell renal cell carcinoma to navitoclax through a STAT3/BCL-XL pathway.奥沙拉嗪通过STAT3/BCL-XL途径使透明细胞肾细胞癌对维托克拉克斯敏感。
Cancer Lett. 2025 Mar 31;613:217514. doi: 10.1016/j.canlet.2025.217514. Epub 2025 Jan 31.
7
Ribonucleotide reductase small subunit M2 promotes the proliferation of esophageal squamous cell carcinoma cells HuR-mediated mRNA stabilization.核糖核苷酸还原酶小亚基M2通过HuR介导的mRNA稳定性促进食管鳞状细胞癌细胞增殖。
Acta Pharm Sin B. 2024 Oct;14(10):4329-4344. doi: 10.1016/j.apsb.2024.07.022. Epub 2024 Aug 3.
8
EWS-FLI1 and Activator Protein-1 (AP-1) Reciprocally Regulate Extracellular-Matrix Proteins in Ewing sarcoma Cells.EWS-FLI1 和激活蛋白 1（AP-1）在尤文肉瘤细胞中相互调节细胞外基质蛋白。
Int J Mol Sci. 2024 Aug 6;25(16):8595. doi: 10.3390/ijms25168595.
9
Auranofin and reactive oxygen species inhibit protein synthesis and regulate the level of the PLK1 protein in Ewing sarcoma cells.金诺芬和活性氧抑制尤因肉瘤细胞中的蛋白质合成并调节PLK1蛋白水平。
Front Oncol. 2024 Jun 12;14:1394653. doi: 10.3389/fonc.2024.1394653. eCollection 2024.
10
A comprehensive analysis of ribonucleotide reductase subunit M2 for carcinogenesis in pan-cancer.泛癌中核糖核苷酸还原酶亚基 M2 致癌作用的综合分析。
PLoS One. 2024 Apr 18;19(4):e0299949. doi: 10.1371/journal.pone.0299949. eCollection 2024.
羟脲和 CHK1 抑制剂联合使用能有效控制黑色素瘤和肺癌的进展，与吉西他滨相比，正常组织毒性降低。
Mol Oncol. 2019 Jul;13(7):1503-1518. doi: 10.1002/1878-0261.12497. Epub 2019 Jun 14.
4
Ewing sarcoma.尤因肉瘤。
Nat Rev Dis Primers. 2018 Jul 5;4(1):5. doi: 10.1038/s41572-018-0003-x.
5
Inhibition of CHK1 sensitizes Ewing sarcoma cells to the ribonucleotide reductase inhibitor gemcitabine.CHK1的抑制使尤因肉瘤细胞对核糖核苷酸还原酶抑制剂吉西他滨敏感。
Oncotarget. 2017 Jun 28;8(50):87016-87032. doi: 10.18632/oncotarget.18776. eCollection 2017 Oct 20.
6
Ribonucleotide reductase represents a novel therapeutic target in primary effusion lymphoma.核糖核苷酸还原酶是原发性渗出性淋巴瘤中的一个新的治疗靶点。
Oncogene. 2017 Aug 31;36(35):5068-5074. doi: 10.1038/onc.2017.122. Epub 2017 May 1.
7
Gene expression signature based screening identifies ribonucleotide reductase as a candidate therapeutic target in Ewing sarcoma.基于基因表达特征的筛选将核糖核苷酸还原酶鉴定为尤因肉瘤的候选治疗靶点。
Oncotarget. 2016 Sep 27;7(39):63003-63019. doi: 10.18632/oncotarget.11416.
8
Ewing Sarcoma: Current Management and Future Approaches Through Collaboration.尤因肉瘤：通过合作实现的当前管理和未来方法。
J Clin Oncol. 2015 Sep 20;33(27):3036-46. doi: 10.1200/JCO.2014.59.5256. Epub 2015 Aug 24.
9
Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies.核糖核苷酸还原酶与癌症：生物学机制及靶向治疗
Oncogene. 2015 Apr 16;34(16):2011-21. doi: 10.1038/onc.2014.155. Epub 2014 Jun 9.
10
A small-molecule blocking ribonucleotide reductase holoenzyme formation inhibits cancer cell growth and overcomes drug resistance.小分子阻断核糖核苷酸还原酶全酶形成可抑制癌细胞生长并克服耐药性。
Cancer Res. 2013 Nov 1;73(21):6484-93. doi: 10.1158/0008-5472.CAN-13-1094. Epub 2013 Sep 26.